Neoadjuvant Therapy for Gastric Cancer

Advances in Surgery

Volumn 42, Issue C, 2008, Pages 151-168

  House, Michael G ^a   Brennan, Murray F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADJUVANT THERAPY; CANCER STAGING; HUMAN; LYMPHADENECTOMY; MORTALITY; PATHOLOGY; REVIEW; STOMACH TUMOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; HUMANS; LYMPH NODE EXCISION; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 49849084228     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yasu.2008.04.003     Document Type: Review

References (57)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
2. Minino A.M., Heron M.P., Murphy S.L., et al. Deaths: final data for 2004. Natl Vital Stat Rep 55 19 (2007) 1-119
3. Jemal A., Clegg L.X., Ward E., et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101 1 (2004) 3-27
4. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 1 (2004) 8-29
5. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 5 1 (2002) 1-5
6. Wanebo H.J., Kennedy B.J., Chmiel J., et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 218 5 (1993) 583-592
7. Ajani J.A., Mansfield P.F., Janjan N., et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22 14 (2004) 2774-2780
8. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 1 (2006) 11-20
9. Jinawath N., Furukawa Y., Hasegawa S., et al. Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene 23 40 (2004) 6830-6844
10. Mansour J.C., Tang L., Shah M., et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?. Ann Surg Oncol 14 12 (2007) 3412-3418
11. Hartgrink H.H., Putter H., Klein Kranenbarg E., et al. Value of palliative resection in gastric cancer. Br J Surg 89 11 (2002) 1438-1443
12. Burke E.C., Karpeh M.S., Conlon K.C., et al. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg 225 3 (1997) 262-267
13. Conlon K.C. Staging laparoscopy for gastric cancer. Ann Ital Chir 72 1 (2001) 33-37
14. Bentrem D., Wilton A., Mazumdar M., et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 12 5 (2005) 347-353
15. Botet J.F., Lightdale C.J., Zauber A.G., et al. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. Radiology 181 2 (1991) 426-432
16. Habermann C.R., Weiss F., Riecken R., et al. Preoperative staging of gastric adenocarcinoma: comparison of helical CT and endoscopic US. Radiology 230 2 (2004) 465-471
17. Bentrem D., Gerdes H., Tang L., et al. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol 14 6 (2007) 1853-1859
18. Tsendsuren T., Jun S.M., and Mian X.H. Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer. World J Gastroenterol 12 1 (2006) 43-47
19. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC cancer staging manual. 6th edition (2002), Springer-Verlag, New York
20. Gold J.S., Jaques D.P., Bentrem D.J., et al. Outcome of patients with known metastatic gastric cancer undergoing resection with therapeutic intent. Ann Surg Oncol 14 2 (2007) 365-372
21. Sarela A.I., Miner T.J., Karpeh M.S., et al. Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg 243 2 (2006) 189-195
22. Kattan M.W., Karpeh M.S., Mazumdar M., et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 21 19 (2003) 3647-3650
23. Novotny A.R., Schuhmacher C., Busch R., et al. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 243 1 (2006) 74-81
24. D'Angelica M., Gonen M., Brennan M.F., et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 240 5 (2004) 808-816
25. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 10 (2001) 725-730
26. Breslin T.M., Hess K.R., Harbison D.B., et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8 2 (2001) 123-132
27. Guillem J.G., Puig-La Calle Jr. J., Akhurst T., et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 43 1 (2000) 18-24
28. Lowy A.M., Mansfield P.F., Leach S.D., et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229 3 (1999) 303-308
29. Ruo L., Tickoo S., Klimstra D.S., et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 236 1 (2002) 75-81
30. Ott K., Fink U., Becker K., et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21 24 (2003) 4604-4610
31. Ott K., Weber W.A., Lordick F., et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24 29 (2006) 4692-4698
32. Potti A., Dressman H.K., Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 12 11 (2006) 1294-1300
33. Zhang Z.X., Gu X.Z., Yin W.B., et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys 42 5 (1998) 929-934
34. Ajani J.A., Mansfield P.F., Lynch P.M., et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 17 8 (1999) 2403-2411
35. Ajani J.A., Mayer R.J., Ota D.M., et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 85 22 (1993) 1839-1844
36. Ajani J.A., Ota D.M., Jessup J.M., et al. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 68 7 (1991) 1501-1506
37. Brenner B., Shah M.A., Karpeh M.S., et al. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol 17 9 (2006) 1404-1411
38. Kelsen D., Karpeh M., Schwartz G., et al. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 14 6 (1996) 1818-1828
39. Lowy A.M., Feig B.W., Janjan N., et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 8 6 (2001) 519-524
40. Ajani J.A., Mansfield P.F., Crane C.H., et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23 6 (2005) 1237-1244
41. Ajani J.A., Winter K., Okawara G.S., et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 24 24 (2006) 3953-3958
42. Bonenkamp J.J., Hermans J., Sasako M., et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 340 12 (1999) 908-914
43. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79 9-10 (1999) 1522-1530
44. Maruyama K., Sasako M., Kinoshita T., et al. Should systematic lymph node dissection be recommended for gastric cancer?. Eur J Cancer 34 10 (1998) 1480-1489
45. Karpeh M.S., Leon L., Klimstra D., et al. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg 232 3 (2000) 362-371
46. Barbour A.P., Rizk N.P., Gonen M., et al. Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome. Ann Surg Oncol 14 2 (2007) 306-316
47. Harrison L.E., Karpeh M.S., and Brennan M.F. Total gastrectomy is not necessary for proximal gastric cancer. Surgery 123 2 (1998) 127-130
48. Kim S.H., Karpeh M.S., Klimstra D.S., et al. Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg 3 1 (1999) 24-33
49. Bajetta E., Buzzoni R., Mariani L., et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian trials in medical oncology (ITMO) group. Ann Oncol 13 2 (2002) 299-307
50. Coombes R.C., Schein P.S., Chilvers C.E., et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International collaborative cancer group. J Clin Oncol 8 8 (1990) 1362-1369
51. Imanaga H., and Nakazato H. Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg 2 1 (1977) 213-221
52. Nakajima T., Fukami A., Ohashi I., et al. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm 16 5 (1978) 209-216
53. Mari E., Floriani I., Tinazzi A., et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo studio dei carcinomi dell'apparato digerente). Ann Oncol 11 7 (2000) 837-843
54. Findlay M., Cunningham D., Norman A., et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5 7 (1994) 609-616
55. Zaniboni A., Barni S., Labianca R., et al. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian group for the study of digestive tract cancer (GISCAD) report. Cancer 76 10 (1995) 1694-1699
56. Bleiberg H., Goffin J.C., Dalesio O., et al. Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. Eur J Surg Oncol 15 6 (1989) 535-543
57. Dent D.M., Werner I.D., Novis B., et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 44 2 (1979) 385-391